PT2477649T - Vacina contra a diarreia devida a e. coli enterotoxigênica (etec) e a cólera - Google Patents

Vacina contra a diarreia devida a e. coli enterotoxigênica (etec) e a cólera

Info

Publication number
PT2477649T
PT2477649T PT108175209T PT10817520T PT2477649T PT 2477649 T PT2477649 T PT 2477649T PT 108175209 T PT108175209 T PT 108175209T PT 10817520 T PT10817520 T PT 10817520T PT 2477649 T PT2477649 T PT 2477649T
Authority
PT
Portugal
Prior art keywords
etec
enterotoxigenic
diarrhea
coli
vaccine against
Prior art date
Application number
PT108175209T
Other languages
English (en)
Portuguese (pt)
Inventor
Holmgren Jan
Lebens Michael
Original Assignee
Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Msd Wellcome Trust Hilleman Laboratories Pvt Ltd filed Critical Msd Wellcome Trust Hilleman Laboratories Pvt Ltd
Publication of PT2477649T publication Critical patent/PT2477649T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PT108175209T 2009-09-16 2010-09-16 Vacina contra a diarreia devida a e. coli enterotoxigênica (etec) e a cólera PT2477649T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27235109P 2009-09-16 2009-09-16

Publications (1)

Publication Number Publication Date
PT2477649T true PT2477649T (pt) 2017-03-01

Family

ID=43758898

Family Applications (1)

Application Number Title Priority Date Filing Date
PT108175209T PT2477649T (pt) 2009-09-16 2010-09-16 Vacina contra a diarreia devida a e. coli enterotoxigênica (etec) e a cólera

Country Status (15)

Country Link
US (1) US9511133B2 (enExample)
EP (1) EP2477649B1 (enExample)
JP (2) JP2013505017A (enExample)
KR (1) KR101722802B1 (enExample)
CN (1) CN102630166B (enExample)
AU (1) AU2010296065B2 (enExample)
CA (1) CA2774335C (enExample)
DK (1) DK2477649T3 (enExample)
ES (1) ES2616912T3 (enExample)
HU (1) HUE031957T2 (enExample)
IN (1) IN2012DN02860A (enExample)
PL (1) PL2477649T3 (enExample)
PT (1) PT2477649T (enExample)
WO (1) WO2011034495A1 (enExample)
ZA (1) ZA201202710B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CN102824632A (zh) * 2012-09-12 2012-12-19 北京民海生物科技有限公司 霍乱弧菌o1群多糖结合疫苗、其制备方法及应用
RU2535122C1 (ru) * 2013-11-06 2014-12-10 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения холерогена-анатоксина
RU2563620C2 (ru) * 2014-08-05 2015-09-20 Федеральное казенное учреждение здравоохранения "Российский научно-исследовательский противочумный институт "Микроб" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека ("РосНИПЧИ "Микроб") Способ получения таблетированной формы холерной бивалентной химической вакцины
US10987415B2 (en) * 2015-12-14 2021-04-27 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. Process for production of purified recombinant cholera toxin B (rCTB) and formulation thereon
JP6820565B2 (ja) * 2016-04-27 2021-01-27 国立大学法人大阪大学 病原性細菌の定着を阻害するペプチド及びそれを含む定着阻害剤
WO2019115001A1 (en) 2017-12-15 2019-06-20 Valneva Sweden Ab Methods and compositions for preventing and/or treating cancer
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera
JP2022545265A (ja) * 2019-08-20 2022-10-26 ニューリタス リミテッド 筋萎縮を治療するためのペプチド
WO2021105061A1 (en) 2019-11-25 2021-06-03 Gotovax Ab Whole cell vaccines and methods of production thereof
WO2022074061A1 (en) 2020-10-07 2022-04-14 Valneva Sweden Ab Cholera vaccine formulation
WO2022117823A1 (en) 2020-12-04 2022-06-09 Valneva Se Methods and compositions for preventing and/or treating autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882653A (en) 1983-03-04 1999-03-16 The University Of Maryland System Vibrio cholerae 01 (CVD111) and non-01 (CVD112 and CVD112RM) serogroup vaccine strains, methods of making same and products thereof
US5330753A (en) * 1987-04-29 1994-07-19 President And Fellows Of Harvard College Cholera vaccines
ATE242319T1 (de) * 1992-07-06 2003-06-15 Harvard College Deletionsmutanten als impfstoffe gegen cholera
US6203799B1 (en) 1993-07-01 2001-03-20 Presidents And Fellows Of Harvard College Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
WO2000067784A1 (en) 1999-05-10 2000-11-16 University Of Maryland, Baltimore Bacteriophage isolated from bacterial genomes and extrachromosomal elements and methods of use thereof
US7270961B2 (en) 2002-04-16 2007-09-18 Hui Sunny Chang In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes
US20060171966A1 (en) 2002-08-30 2006-08-03 Centre For Health And Population Research Variants of vibrio cholerae 01 biotype e1 tor with attributes of classical biotype
CU23334A1 (es) * 2003-03-20 2008-12-24 Inst Finlay Vacuna de vibrio cholerae inactivada en tabletas
US20060099229A1 (en) 2004-11-05 2006-05-11 Universiti Sains Malaysia Vibrio cholerae strains VCUSM1 and VCUSM4, method of producing same, and vaccine derivatives thereof
EP1543836A1 (en) * 2003-12-17 2005-06-22 Berna Biotech AG Recombinant Vibrio cholerae strain and vaccine comprising said strain
WO2009049013A2 (en) * 2007-10-09 2009-04-16 Tufts University Cholera vaccines

Also Published As

Publication number Publication date
US9511133B2 (en) 2016-12-06
ZA201202710B (en) 2015-12-23
CA2774335C (en) 2016-10-18
JP2013505017A (ja) 2013-02-14
EP2477649A1 (en) 2012-07-25
CN102630166B (zh) 2015-08-05
IN2012DN02860A (enExample) 2015-06-19
KR20120081600A (ko) 2012-07-19
CN102630166A (zh) 2012-08-08
EP2477649B1 (en) 2016-11-23
PL2477649T3 (pl) 2017-06-30
DK2477649T3 (en) 2017-03-06
JP2016074695A (ja) 2016-05-12
EP2477649A4 (en) 2013-01-30
KR101722802B1 (ko) 2017-04-03
US20120276146A1 (en) 2012-11-01
CA2774335A1 (en) 2011-03-24
JP6178384B2 (ja) 2017-08-09
HUE031957T2 (en) 2017-09-28
AU2010296065B2 (en) 2015-05-21
ES2616912T3 (es) 2017-06-14
WO2011034495A1 (en) 2011-03-24
AU2010296065A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
PL2477649T3 (pl) Szczepionka przeciwko biegunce powodowanej przez cholerę i enterotoksynogenną e. coli (etec)
IL207482A0 (en) Devices, methods and sysems for control of heliostats
EP2300553A4 (en) HEAT TRANSFER SYSTEM, LIQUID AND METHOD
PL2331651T3 (pl) Czynnik do przenoszenia ciepła
EG25169A (en) Cementing valve.
EP2427237A4 (en) FLUID TRANSFER DEVICE
SG10201405839XA (en) Fluid transfer device and system
AP2011005821A0 (en) Processing biomas.
BRPI1014852A2 (pt) acoplamento tipo de crimpagem, ferramenta de crimpagem e método de crimpagem.
EP2447229A4 (en) GLASS SHIELD AGAINST THERMAL RAYS, AND LAMINATED SHIELDING GLASS AGAINST THERMAL RAYS
PL2318047T3 (pl) Probiotyki, wydzielnicze iga a zakażenie
ZA200904060B (en) Salmonella vaccine
ZA201002445B (en) Hiv preventive vaccine based on hiv specific antibodies
EP2162460A4 (en) VACCINES AGAINST CHLAMYDIA INFECTIONS
LU91570B1 (en) Arrangement for burning blast furnace off-gas froma bleeder valve and corresponding bleeder valve.
GB2456401A9 (en) Ion handling devices.
EP2377605A4 (en) LIQUID WAY STRUCTURE, REACTOR AND REACTION PROCESS WITH THE REACTOR
PL2306960T3 (pl) Zespół przenoszenia płynu
AP2012006303A0 (en) Anti-trypanosomiasis vaccines and diagnostics.
GB2448236B (en) Transfer valve
HUE036822T2 (hu) CGNC alkalmazásra H. pylori fertõzésben
EP2231534B8 (en) Bottle transfer assembly and components for use therein
GB0816395D0 (en) Valve medium processing device
TWI346557B (en) Adjuvant and vaccine includes the same
GB0722490D0 (en) The K energy syndrome